MDGL files 8-K — Item 2.02 Results of Operations

Madrigal Pharmaceuticals, Inc. (MDGL), a clinical-stage biopharmaceutical company with a $11.5B market capitalization, filed an 8-K with the SEC disclosing Item 2.02 (Results of Operations and Financial Data) on May 6, 2026, at 07:06:34 ET, per EDGAR filing accession number 000162828026030896. The company concurrently submitted a 10-Q for the three months ended March 31, 2026, per EDGAR 000162828026030947.

What Was Filed

Item 2.02 is the SEC’s plain-language category for public companies to disclose material quarterly financial results and accompanying corporate updates. For biotech firms like MDGL, this filing typically accompanies a scheduled earnings release, providing preliminary financial metrics and high-level pipeline highlights without full granular detail.

The Disclosure

Per provided earnings data, MDGL reported first-quarter 2026 GAAP EPS of -$3.25, beating consensus estimates of -$4.23, and total revenue of $311.34 million, exceeding consensus forecasts of $301.05 million. This marks the second consecutive quarter of revenue beats, following the fourth-quarter 2025 report where revenue hit $321.10 million vs estimates of $312.51 million, with EPS of -$2.57 vs a consensus estimate of $0.04.

Cross-Referenced Prior Signals

This earnings filing aligns with three pre-existing data points: first, the analyst rating distribution has remained static since February 2026, with 3 Strong Buy, 11 Buy, and 2 Hold ratings, no Sell or Strong Sell coverage. Second, on March 6, 2026, EVP and CFO Dier Mardi filed 10 Form 4 transactions selling a total of 1,782 MDGL shares for aggregate proceeds of approximately $766,725, just two months prior to the earnings beat announcement. Third, the December 31, 2025 13F filing shows 412 institutional holders, a 29-quarter-over-quarter increase, with total institutional ownership of 104.8% of the company’s float, indicating broad institutional positioning ahead of the earnings release.

Unanswered Critical Data Points

Three key details are not included in the 8-K filing: 1) Full breakdown of lead product resmetirom sales and clinical trial update details, as the filing only incorporates the accompanying press release by reference rather than including granular data; 2) Specific terms of the May 5, 2026 licensing agreement for a PNPLA3-targeted siRNA asset, announced the day before the 8-K filing but not referenced in the Item 2.02 disclosure; and 3) Updated institutional ownership figures, as the latest available 13F data is six weeks stale ahead of the earnings release.